PURPOSE: To determine whether @entity1169 can decrease surgical @entity400 and @entity148 in residents performing ocular microsurgery without impairing @entity1 or physician safety. METHODS: In this randomized, double-masked, crossover study, 5 third-year ophthalmology residents ingested a capsule containing either @entity1169 , 40 mg, or placebo 1 hour prior to performing ophthalmic microsurgery. All residents were healthy @entity1 under age 30 years. Prior to commencement of the study, all @entity1 had successfully been administered a test dose of @entity1169 without side effects. The study took place over a 10-week period. At the conclusion of each case, both the resident and attending surgeon observer independently completed a form grading, on a sliding scale: (1) amount of overall @entity400 ; (2) amount of @entity400 during placement of the first 3 sutures after lens or nucleus extraction; (3) anticipated difficulty of the case; (4) actual difficulty with the case; and (5) @entity148 (surgeon only). In addition, the type of procedure performed, complications encountered, and surgeon side effects were recorded. The data were analyzed with a 2-way analysis of variance for unbalanced data. RESULTS: A total of 73 surgical cases were performed; the surgeons were administered @entity1169 for 40 cases and placebo for 33. As judged by the resident surgeon, there was a highly significant effect of @entity1169 in decreasing @entity148 (P = .0058), reducing surgical @entity400 overall (P < .0001), and reducing @entity400 while placing the first 3 sutures following lens extraction (P < .0001). There was no treatment-by-surgeon interaction for any of the measures. Complications and difficulty of the case, as judged by both the resident and attending surgeons, were not significantly different in the @entity1169 versus placebo groups (P > .05). There were no side effects reported or observed in any of the surgeons. CONCLUSIONS: @entity1169 , 40 mg, administered 1 hour prior to surgery, significantly decreases @entity400 and @entity148 in the surgeon without untoward effects to the surgeon and the @entity1 . However, it is unknown whether decreased @entity400 and @entity148 improved surgical outcome.

The effect of XXXX versus placebo on resident surgical performance.

@entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol', 'Propranolol'] @entity1 :: ('9606', 'Species') :: ['participants', 'patient', 'men'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety']
@entity1169 :: (MESH:D011433,Chemical) :: ['propranolol']
